Attached files
file | filename |
---|---|
8-K - FORM 8-K - SS&C Technologies Holdings Inc | b87380e8vk.htm |
EX-99.2 - EX-99.2 - SS&C Technologies Holdings Inc | b87380exv99w2.htm |
EX-99.1 - EX-99.1 - SS&C Technologies Holdings Inc | b87380exv99w1.htm |
Exhibit 1.1
7,000,000 Shares
SS&C TECHNOLOGIES HOLDINGS, INC.
COMMON STOCK ($0.01 PAR VALUE PER SHARE)
UNDERWRITING AGREEMENT
July 21, 2011
July 21, 2011
Barclays Capital Inc.
745 Seventh Avenue
New York, New York 10019
745 Seventh Avenue
New York, New York 10019
Ladies and Gentlemen:
SS&C Technologies Holdings, Inc., a Delaware corporation (the Company), and the
persons named in Schedule I to this Agreement (the Selling Stockholders) confirm
their respective agreements with Barclays Capital Inc. (the Underwriter), with respect to
the sale by the Selling Stockholders, acting severally and not jointly, and the purchase by the
Underwriter of 7,000,000 shares of the common stock ($0.01 par value per share) of the Company (the
Shares), with each Selling Stockholder selling the amount set forth opposite such Selling
Stockholders name in Schedule I hereto. The shares of common stock of the Company are
hereinafter referred to as the Common Stock.
The Company has filed with the Securities and Exchange Commission (the Commission) a
shelf registration statement on Form S-3 (File No. 333-174709), including a prospectus relating to
the Shares, under the Securities Act of 1933, as amended (the Securities Act), which
registration statement became effective on July 12, 2011. Such registration statement, as of any
time, means such registration statement as amended by any post-effective amendments thereto to such
time, including the exhibits and any schedules thereto at such time, the documents incorporated or
deemed to be incorporated by reference therein at such time pursuant to Item 12 of Form S-3 under
the Securities Act and the information otherwise deemed to be a part thereof as of such time
pursuant to Rule 430B under the Securities Act (Rule 430B), and is hereinafter referred
to as the Registration Statement; provided, however, that the Registration Statement
without reference to a time means such registration statement as amended by any post-effective
amendments thereto as of the time of the first contract of sale for the Shares, which time shall be
considered the new effective date of such registration statement with respect to the
Shares within the meaning of paragraph (f)(2) of Rule 430B, including the exhibits and schedules
thereto as of such time, the documents incorporated or deemed incorporated by reference therein at
such time pursuant to Item 12 of Form S-3 under the Securities Act and the information otherwise
deemed to be a part thereof as of such time pursuant to Rule 430B. Promptly after execution and
delivery of this Agreement, the Company will prepare and file a final prospectus supplement
relating to the Shares in accordance with the provisions of Rule 424(b) under the Securities Act
(Rule 424(b)). The final prospectus, in the form first furnished or made available to
the Underwriter for use in connection with the offering of the Shares, including the documents
incorporated or deemed incorporated by reference therein pursuant to Item 12 of Form S-3 under the
Securities Act, are collectively referred to herein as the Prospectus. For purposes of
this Agreement, all references to the Registration Statement, the Prospectus or any amendment or
supplement to either of the foregoing shall be deemed to include the copy filed with the Commission
pursuant to its Electronic Data Gathering, Analysis and Retrieval system (or any successor system
(EDGAR) and any documents filed after such date under the Securities Exchange Act of
1934, as amended, and the rules and regulations of the Commission thereunder (collectively, the
Exchange Act) that are deemed to be incorporated by reference therein.
For purposes of this Agreement, free writing prospectus has the meaning set forth in
Rule 405 under the Securities Act, Time of Sale Prospectus means the base prospectus
filed as part of the Registration Statement, in the form most recently amended on or prior to the
date of this Agreement, together with the free writing prospectuses, if any, and the term sheets
communicated pursuant to Rule 134 under the Securities Act, if any, each as identified in
Schedule II hereto and the other information set forth on Schedule II hereto, and
broadly available road show means a bona fide electronic road show as defined in Rule
433(h)(5) under the Securities Act that has been made available without restriction to any person.
As used herein, the terms Registration Statement, Time of Sale Prospectus and Prospectus
shall include the documents, if any, incorporated by reference therein.
1. Representations and Warranties of the Company. The Company represents and warrants
to and agrees with the Underwriter that:
(a) (i) At the time the Registration Statement was originally filed, (ii) at the time of the
most recent amendment thereto for the purposes of complying with Section 10(a)(3) of the Securities
Act (whether such amendment was by post-effective amendment, incorporated report filed pursuant to
Section 13 or 15(d) of the Exchange Act), and (iii) at the date hereof, the Company met or meets
the requirements for use of Form S-3 under the Securities Act. The Registration Statement is a
shelf registration statement and the Shares have been and remain eligible for registration by the
Company on such shelf registration statement. Each of the Registration Statement and any
post-effective amendment thereto has been declared effective under the Securities Act. No stop
order suspending the effectiveness of the Registration Statement or any post-effective amendment
thereto has been issued under the Securities Act, no order preventing or suspending the use of the
Prospectus has been issued and no proceedings for any of those purposes have been instituted or are
pending or, to the Companys knowledge, contemplated. The Company has complied with each request
(if any) from the Commission for additional information. Each of the Registration Statement and
any post-effective amendment thereto, at the time of its effectiveness and at each deemed effective
date with respect to the Underwriter pursuant to Rule 430B(f)(2) under the Securities Act, complied
in all material respects with the requirements of the Securities Act and the applicable rules and
regulations of the Commission thereunder. The Prospectus and any amendment or supplement thereto,
at the time each was filed with the Commission, complied in all material respects with the
requirements of the applicable rules and regulations of the Commission under the Securities Act and
the Prospectus delivered to the Underwriter for use in connection with this offering was identical
to the electronically transmitted copies thereof filed with the Commission pursuant to EDGAR,
except to the extent permitted by Regulation S-T. The documents incorporated or deemed to be
incorporated by reference in the Registration Statement and the Prospectus, when they became
effective or at the time they were or hereafter are filed with the Commission, conformed in all
material respects to the requirements of the Exchange Act, and none of such documents contained any
untrue statement of a material fact or omitted to state a material fact necessary to make the
statements therein, in the light of the circumstances under which they were made, not misleading;
and any further documents so filed and incorporated by reference in the Registration Statement, the
Time of Sale Prospectus or the Prospectus, when such documents are filed with the Commission, will
conform in all material respects to the requirements of the Exchange Act and will not contain any
untrue statement of a material fact or omit to state a
- 2 -
material fact necessary to make the statements therein, in the light of the circumstances
under which they were made, not misleading.
(b) (i) The Registration Statement, when it became effective, did not contain and, as amended
or supplemented, if applicable, will not contain any untrue statement of a material fact or omit to
state a material fact required to be stated therein or necessary to make the statements therein not
misleading, (ii) the Registration Statement and the Prospectus comply and, as amended or
supplemented, if applicable, will comply in all material respects with the Securities Act and the
applicable rules and regulations of the Commission thereunder, (iii) the Time of Sale Prospectus
does not, and at the time of each sale of the Shares in connection with the offering when the
Prospectus is not yet available to prospective purchasers and at the Closing Date (as defined in
Section 5), the Time of Sale Prospectus, as then amended or supplemented by the Company, if
applicable, will not, contain any untrue statement of a material fact or omit to state a material
fact necessary to make the statements therein, in the light of the circumstances under which they
were made, not misleading, (iv) each broadly available road show, if any, when considered together
with the Time of Sale Prospectus, does not contain any untrue statement of a material fact or omit
to state a material fact necessary to make the statements therein, in the light of the
circumstances under which they were made, not misleading and (v) the Prospectus does not contain
and, as amended or supplemented, if applicable, will not contain any untrue statement of a material
fact or omit to state a material fact necessary to make the statements therein, in the light of the
circumstances under which they were made, not misleading, except that the representations and
warranties set forth in this paragraph do not apply to statements or omissions in the Registration
Statement, the Time of Sale Prospectus or the Prospectus based upon information relating to the
Underwriter furnished to the Company in writing by the Underwriter expressly for use therein.
(c) The Company is not an ineligible issuer in connection with the offering pursuant to
Rules 164, 405 and 433 under the Securities Act. Any free writing prospectus that the Company is
required to file pursuant to Rule 433(d) under the Securities Act has been, or will be, filed with
the Commission in accordance with the requirements of the Securities Act and the applicable rules
and regulations of the Commission thereunder. Each free writing prospectus that the Company has
filed, or is required to file, pursuant to Rule 433(d) under the Securities Act or that was
prepared by or behalf of or used or referred to by the Company complies or will comply in all
material respects with the requirements of the Securities Act and the applicable rules and
regulations of the Commission thereunder. Except for the free writing prospectuses, if any,
identified in Schedule II hereto, and electronic road shows, if any, each furnished to the
Underwriter before first use, the Company has not prepared, used or referred to, and will not,
without your prior consent, prepare, use or refer to, any free writing prospectus.
(d) The Company has been duly incorporated, is validly existing as a corporation in good
standing under the laws of the jurisdiction of its incorporation, has the corporate power and
authority to own its property and to conduct its business as described in the Time of Sale
Prospectus and is duly qualified to transact business and is in good standing in each jurisdiction
in which the conduct of its business or its ownership or leasing of property requires such
qualification, except to the extent that the failure to be so qualified or be in good standing
would not have a material adverse effect on the Company and its subsidiaries, taken as a whole.
- 3 -
(e) Each subsidiary of the Company has been duly organized, is validly existing as an entity
in good standing under the laws of the jurisdiction of its organization, has the power and
authority to conduct its business as currently conducted and to own and lease the properties it now
owns and leases and is duly qualified to transact business and is in good standing in each
jurisdiction in which the conduct of its business or its ownership or leasing of property requires
such qualification, except to the extent that the failure to be so qualified or be in good standing
would not have a material adverse effect on the Company and its subsidiaries, taken as a whole; all
of the issued shares of capital stock or equity interests of each subsidiary of the Company have
been duly and validly authorized and issued, are fully paid and non-assessable (to the extent
legally applicable) and, except as disclosed in the Time of Sale Prospectus and except for
directors qualifying shares, are owned directly or indirectly by the Company, free and clear of
all liens, encumbrances, equities or claims.
(f) The Company has full right, power and authority to execute and deliver this Agreement and
to perform its obligations hereunder; and all action required to be taken for the due and proper
authorization, execution and delivery by it of this Agreement and the consummation by it of the
transactions contemplated hereby has been duly and validly taken.
(g) This Agreement has been duly authorized, executed and delivered by the Company.
(h) The authorized capital stock of the Company conforms as to legal matters in all material
respects to the description thereof contained in each of the Time of Sale Prospectus and the
Prospectus.
(i) The outstanding shares of Common Stock have been duly authorized and are validly issued,
fully paid and non assessable.
(j) The Shares to be sold by the Selling Stockholders have been duly authorized, and none of
such Shares were issued in violation of any preemptive or similar rights.
(k) Neither the Company nor any of its subsidiaries is (i) in violation of its certificate of
incorporation or by-laws or similar organizational documents; (ii) in default, and no event has
occurred that, with notice or lapse of time or both, would constitute such a default, in the due
performance or observance of any term, covenant or condition contained in any indenture, mortgage,
deed of trust, loan agreement or other agreement or instrument to which the Company or any of its
subsidiaries is a party or by which the Company or any of its subsidiaries is bound or to which any
of the property or assets of the Company or any of its subsidiaries is subject; or (iii) in
violation of any law or statute or any judgment, order, rule or regulation of any court or
arbitrator or governmental or regulatory authority, except, in the case of clauses (ii) and (iii)
above, for any such default or violation that would not be materially adverse to the Company and
its subsidiaries, taken as a whole.
(l) The execution and delivery by the Company of, and the performance by the Company of its
obligations under, this Agreement, and the consummation of the transactions herein contemplated
will not contravene (i) any provision of applicable law, (ii) the certificate of incorporation or
by-laws of the Company, (iii) any agreement or other instrument binding upon
- 4 -
the Company or any of its subsidiaries or (iv) any judgment, order or decree of any
governmental body, agency or court having jurisdiction over the Company or any subsidiary, except
in the case of clauses (iii) and (iv), for any such contravention that would not affect the
validity of the Shares or otherwise be materially adverse to the Company and its subsidiaries,
taken as a whole, and no consent, approval, authorization or order of, or qualification with, any
governmental body or agency is required for the performance by the Company of its obligations under
this Agreement, except for the registration of the Shares under the Securities Act, such consents,
approvals, authorizations, orders or qualifications as may be required by the Financial Industry
Regulatory Authority, Inc. (FINRA) and by the securities or Blue Sky laws of the various
states in connection with the offer and sale of the Shares.
(m) There has not occurred any material adverse change, or any development involving a
prospective material adverse change, in the condition, financial or otherwise, or in the earnings,
business, management, financial position, stockholders equity or operations of the Company and its
subsidiaries, taken as a whole, from that set forth in the Time of Sale Prospectus.
(n) There are no legal or governmental proceedings pending or, to the knowledge of the
Company, threatened to which the Company or any of its subsidiaries is a party or to which any of
the properties of the Company or any of its subsidiaries is subject (i) other than proceedings
accurately described in all material respects in the Time of Sale Prospectus and proceedings that
would not have a material adverse effect on the Company and its subsidiaries, taken as a whole, or
on the power or ability of the Company to perform its obligations under this Agreement or to
consummate the transactions contemplated by the Time of Sale Prospectus or (ii) that are required
to be described in the Registration Statement or the Prospectus and are not so described; and there
are no statutes, regulations, contracts or other documents that are required to be described in the
Registration Statement or the Prospectus or to be filed as exhibits to the Registration Statement
that are not described or filed as required.
(o) [Intentionally omitted.]
(p) The Company is not required to register as an investment company as such term is defined
in the Investment Company Act of 1940, as amended.
(q) The Company and its subsidiaries (i) are in compliance with any and all applicable
foreign, federal, state and local laws and regulations relating to the protection of human health
and safety, the environment or hazardous or toxic substances or wastes, pollutants or contaminants
(Environmental Laws), (ii) have received all permits, licenses or other approvals
required of them under applicable Environmental Laws to conduct their respective businesses and
(iii) are in compliance with all terms and conditions of any such permit, license or approval,
except where such noncompliance with Environmental Laws, failure to receive required permits,
licenses or other approvals or failure to comply with the terms and conditions of such permits,
licenses or approvals would not, singly or in the aggregate, have a material adverse effect on the
Company and its subsidiaries, taken as a whole.
(r) There are no costs or liabilities associated with Environmental Laws (including, without
limitation, any capital or operating expenditures required for clean up, closure of
- 5 -
properties or compliance with Environmental Laws or any permit, license or approval, any
related constraints on operating activities and any potential liabilities to third parties) which
would, singly or in the aggregate, have a material adverse effect on the Company and its
subsidiaries, taken as a whole.
(s) Except as disclosed in the Time of Sale Prospectus and as have been complied with in
connection with the offering contemplated hereby, there are no contracts, agreements or
understandings between the Company and any person granting such person the right to require the
Company to file a registration statement under the Securities Act with respect to any securities of
the Company or to require the Company to include such securities with the Shares registered
pursuant to the Registration Statement.
(t) Subsequent to the respective dates as of which information is given in each of the
Registration Statement, the Time of Sale Prospectus and the Prospectus, (i) the Company and its
subsidiaries, taken as a whole, have not incurred any material liability or obligation, direct or
contingent, nor entered into any material transaction; (ii) the Company has not purchased any of
its outstanding capital stock, nor declared, paid or otherwise made any dividend or distribution of
any kind on its capital stock other than ordinary and customary dividends; and (iii) there has not
been any material change in the capital stock, short-term debt or long-term debt of the Company and
its subsidiaries, taken as a whole, except in each case as disclosed in each of the Registration
Statement, the Time of Sale Prospectus and the Prospectus, respectively.
(u) Neither the Company nor any of its subsidiaries owns any material real property. The
Company and its subsidiaries have good and valid title to all personal property owned by them which
is material to the business of the Company and its subsidiaries, taken as a whole, in each case
free and clear of all liens, encumbrances and defects except such as are disclosed in the Time of
Sale Prospectus or such as do not materially affect the value of such property and do not interfere
materially with the use made and proposed to be made of such property by the Company and its
subsidiaries; and any real property and buildings held under lease by the Company and its
subsidiaries are held by them under valid, subsisting and enforceable leases with such exceptions
as are not material and do not interfere materially with the use made and proposed to be made of
such property and buildings by the Company and its subsidiaries, in each case except as disclosed
in the Time of Sale Prospectus.
(v) Except as disclosed in the Time of Sale Prospectus, the Company and its subsidiaries own,
possess or have the right to use all material patents, patent rights, licenses, inventions,
copyrights, know-how (including trade secrets and other unpatented and/or unpatentable proprietary
or confidential information, systems or procedures), trademarks, service marks, trade names and
other similar intellectual property rights currently employed by them in connection with the
business now operated by them, and, except as disclosed in the Time of Sale Prospectus, neither the
Company nor any of its subsidiaries has received any written or, to the knowledge of the Companys
officers, oral notice of infringement of or conflict with rights of others with respect to any of
the foregoing that, singly or in the aggregate, if the subject of an unfavorable decision, ruling
or finding, would have a material adverse effect on the Company and its subsidiaries, taken as a
whole; except as disclosed in the Time of Sale Prospectus, the Company and its subsidiaries have
taken all reasonable steps necessary to secure from their employees and contractors assignment of
all rights of such persons in any intellectual property
- 6 -
rights of the Company and its subsidiaries; except as disclosed in the Time of Sale
Prospectus, the Company has no knowledge of any infringement or unauthorized use by any third party
of any intellectual property rights of the Company and its subsidiaries, except for any such
infringement or unauthorized use that would not have a material adverse effect on the Company and
it subsidiaries, taken as a whole; except as disclosed in the Time of Sale Prospectus, the Company
is not aware of outstanding options, licenses or agreements that grant to any third parties rights
under any intellectual property rights of the Company and its subsidiaries which are required to be
set forth in the Time of Sale Prospectus; the Company and its subsidiaries have taken reasonable
measures to prevent the unauthorized dissemination or publication of their confidential information
and, to the extent contractually required to do so, the confidential information of third parties
in their possession.
(w) No material labor dispute with the employees of the Company or any of its subsidiaries
exists, except as disclosed in the Time of Sale Prospectus, or, to the knowledge of the Company, is
imminent; and the Company is not aware of any existing, threatened or imminent labor disturbance by
the employees of any of its principal suppliers, manufacturers or contractors that would reasonably
be expected to have a material adverse effect on the Company and its subsidiaries, taken as a
whole.
(x) The Company and its subsidiaries are insured by insurers of recognized financial
responsibility against such losses and risks and in such amounts as the Company reasonably believes
to be prudent and customary in the businesses in which they are engaged; neither the Company nor
any of its subsidiaries has been refused any insurance coverage sought or applied for; and neither
the Company nor any of its subsidiaries has any reason to believe that it will not be able to renew
its existing insurance coverage as and when such coverage expires or to obtain similar coverage
from similar insurers as may be necessary to continue its business at a cost that would not have a
material adverse effect on the Company and its subsidiaries, taken as a whole, except as disclosed
in the Time of Sale Prospectus.
(y) The Company and its subsidiaries possess all certificates, authorizations and permits
issued by the appropriate federal, state or foreign regulatory authorities necessary to conduct
their respective businesses, other than such certificates, authorizations and permits the failure
to so possess would not reasonably be expected to have a material adverse effect on the Company and
its subsidiaries, taken as a whole, and neither the Company nor any of its subsidiaries has
received any written notice of proceedings relating to the revocation or modification of any such
certificate, authorization or permit which, singly or in the aggregate, if the subject of an
unfavorable decision, ruling or finding, would have a material adverse effect on the Company and
its subsidiaries, taken as a whole, except as disclosed in the Time of Sale Prospectus.
(z) The Company maintains internal control over financial reporting (as defined in Rule
13a-15(f) of the Exchange Act) that complies with the requirements of Rule 13a-15(a) of the
Exchange Act and that has been designed by, or under the supervision of, its principal executive
and principal financial officers, or persons performing similar functions, to provide reasonable
assurance regarding the reliability of financial reporting and the preparation of financial
statements for external purposes in accordance with generally accepted accounting principles,
including, but not limited to, internal accounting controls sufficient to provide
- 7 -
reasonable assurance that (i) transactions are executed in accordance with managements
general or specific authorizations; (ii) transactions are recorded as necessary to permit
preparation of financial statements in conformity with generally accepted accounting principles and
to maintain asset accountability; (iii) access to assets is permitted only in accordance with
managements general or specific authorization; and (iv) the recorded accountability for assets is
compared with the existing assets at reasonable intervals and appropriate action is taken with
respect to any differences. Based on the Companys most recent evaluation of its internal control
over financial reporting pursuant to Rule 13a-15(c) of the Exchange Act, (i) there are no material
weaknesses in the Companys internal control over financial reporting (whether or not remediated)
and (ii) there has been no change in the Companys internal control over financial reporting that
has materially affected, or is reasonably likely to materially affect, the Companys internal
control over financial reporting.
(aa) The Company maintains a system of disclosure controls and procedures (as such term is
defined in Rule 13a-15(e) under Exchange Act) that complies with the requirements of the Exchange
Act and that has been designed to ensure that information required to be disclosed by the Company
in reports that it files or submits under the Exchange Act is recorded, processed, summarized and
reported within the time periods specified in the Commissions rules and forms, including controls
and procedures designed to ensure that such information is accumulated and communicated to the
Companys management as appropriate to allow timely decisions regarding required disclosure. The
Company has carried out evaluations of the effectiveness of its disclosure controls and procedures
as required by Rule 13a-15 of the Exchange Act.
(bb) Except as disclosed in the Registration Statement or the Time of Sale Prospectus, the
Company has not sold, issued or distributed any shares of Common Stock during the six-month period
preceding the date hereof, including any sales pursuant to Rule 144A under, or Regulation D or S
of, the Securities Act, other than shares issued pursuant to employee benefit plans, qualified
stock option plans or other employee compensation plans or pursuant to outstanding options, rights
or warrants.
(cc) To the Companys knowledge, PricewaterhouseCoopers LLP, who have certified certain
financial statements of the Company and its subsidiaries, are independent public accountants as
required by the Securities Act and the rules and regulations of the Commission thereunder.
(dd) The consolidated financial statements and schedules of the Company, and the related notes
thereto, included in or incorporated by reference in the Registration Statement and the Prospectus
present fairly in all material respects the financial position of the Company as of the respective
dates of such financial statements and schedules, and the results of operations and cash flows of
the Company for the respective periods covered thereby; such statements, schedules and related
notes have been prepared in accordance with generally accepted accounting principles in the United
States applied on a consistent basis as certified by the independent public accountants named in
paragraph (cc) above; no other financial statements or schedules are required to be included or
incorporated by reference in the Registration Statement; the pro forma financial information and
the related notes thereto included or incorporated by reference in the Registration Statement, the
Time of Sale Prospectus and the Prospectus have
- 8 -
been prepared in accordance with the applicable requirements of the Securities Act and the
Exchange Act and the assumptions underlying such pro forma financial information are reasonable and
are set forth or incorporated by reference in the Registration Statement, the Time of Sale
Prospectus and the Prospectus.
(ee) With respect to the stock options (the Stock Options) granted pursuant to the
stock-based compensation plans of the Company and its subsidiaries (the Company Stock
Plans), (i) each grant of a Stock Option was duly authorized no later than the date on which
the grant of such Stock Option was by its terms to be effective (the Grant Date) by all
necessary corporate action, including, as applicable, approval by the board of directors of the
Company (or a duly constituted and authorized committee thereof) and any required stockholder
approval by the necessary number of votes or written consents, and the award agreement governing
such grant (if any) was duly executed and delivered by each party thereto, (ii) each such grant was
made in accordance with the terms of the Company Stock Plans and all other applicable laws and
regulatory rules or requirements, and (iii) each such grant was properly accounted for in
accordance with GAAP in the financial statements (including the related notes) of the Company.
(ff) [Intentionally omitted.]
(gg) Other than SS&C Technologies, Inc., SS&C Technologies New Jersey, Inc., SS&C Technologies
Canada Corp. and SS&C Technologies Limited, there are no subsidiaries of the Company that
constitute significant subsidiaries as defined in Rule 1-02 of Regulation S-X (it being
acknowledged and agreed that the Company is making no representation or warranty that the
subsidiaries referred to in this paragraph (gg) are significant subsidiaries as defined in Rule
1-02 of Regulation S-X).
(hh) The statistical and market-related data contained in the Time of Sale Prospectus are
based on or derived from sources which the Company reasonably and in good faith believes are
reliable and accurate, and such data agree with the sources from which they were derived.
(ii) The Company and its subsidiaries have paid all federal, state, local and foreign taxes
and filed all tax returns required to be paid or filed through the date hereof; and except as
otherwise disclosed in the Registration Statement, the Time of Sale Prospectus and the Prospectus,
there is no tax deficiency that has been, or could reasonably be expected to be, asserted against
the Company or any of its subsidiaries or any of their respective properties or assets, except
where such failure to pay or file would not, singly or in the aggregate, have a material adverse
effect on the Company and its subsidiaries, taken as a whole.
(jj) Neither the Company nor any of its subsidiaries nor, to the knowledge of the Company, any
director, officer, agent, employee or other person associated with or acting on behalf of the
Company or any of its subsidiaries has (i) used any corporate funds for any unlawful contribution,
gift, entertainment or other unlawful expense relating to political activity; (ii) made any direct
or indirect unlawful payment to any foreign or domestic government official or employee from
corporate funds; (iii) violated or is in violation of any provision of the Foreign Corrupt
Practices Act of 1977; or (iv) made any bribe, rebate, payoff, influence payment, kickback or other
unlawful payment, which payment, receipt or retention of funds or other
- 9 -
violation is of a character required to be disclosed in the Time of Sale Prospectus and the
Prospectus.
(kk) The operations of the Company and its subsidiaries are and have been conducted at all
times in compliance in all material respects with applicable financial recordkeeping and reporting
requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money
laundering statutes of all jurisdictions, the rules and regulations thereunder and any related or
similar rules, regulations or guidelines, issued, administered or enforced by any governmental
agency (collectively, the Money Laundering Laws) and no action, suit or proceeding by or
before any court or governmental agency, authority or body or any arbitrator involving the Company
or any of its subsidiaries with respect to the Money Laundering Laws is pending or, to the
knowledge of the Company, threatened.
(ll) None of the Company, any of its subsidiaries or, to the knowledge of the Company, any
director, officer, agent, employee or affiliate of the Company or any of its subsidiaries is
currently subject to any U.S. sanctions administered by the Office of Foreign Assets Control of the
U.S. Department of the Treasury (OFAC).
(mm) The Common Stock is listed on The NASDAQ Global Select Market under the symbol SSNC.
If required, the Company has notified The NASDAQ Global Select Market of its intention to list the
Shares on such market. The Company has taken no action designed to, or likely to have the effect
of, terminating the registration of the Common Stock under the Exchange Act or the listing of the
Common Stock on The NASDAQ Global Select Market, nor has the Company received any notification that
the Commission is contemplating terminating such registration or that The NASDAQ Global Select
Market is contemplating terminating such listing.
(nn) The Company has filed on a timely basis with the Commission all reports required by the
Exchange Act. All of such reports when they were filed with the Commission, conformed in all
material respects to the requirements of the Exchange Act.
2. Representations and Warranties of the Selling Stockholders. Each Selling
Stockholder severally and not jointly represents and warrants to and agrees with the Underwriter
that:
(a) This Agreement has been duly authorized, executed and delivered by or on behalf of such
Selling Stockholder.
(b) The execution and delivery by such Selling Stockholder of, and the performance by such
Selling Stockholder of its obligations under, this Agreement will not contravene (i) any provision
of applicable law, (ii) the certificate of incorporation, bylaws, certificate of limited
partnership, limited partnership agreement or other similar organizational agreement of such
Selling Stockholder, (iii) any agreement or other instrument binding upon such Selling Stockholder
or (iv) any judgment, order or decree of any governmental body, agency or court having jurisdiction
over such Selling Stockholder, except in the case of clauses (i), (iii) and (iv), for any such
contravention that would not reasonably be expected to impair in any material respect the
consummation of such Selling Stockholders obligations hereunder.
- 10 -
(c) On the Closing Date (as defined in Section 5) such Selling Stockholder will have
valid title to, or a valid security entitlement within the meaning of Section 8-501 of the New
York Uniform Commercial Code in respect of, the Shares to be sold by such Selling Stockholder free
and clear of all security interests, claims, liens, equities or other encumbrances and the legal
right and power, and all authorization and approval required by law, to enter into this Agreement
and to sell, transfer and deliver the Shares to be sold by such Selling Stockholder or a security
entitlement in respect of such Shares.
(d) Delivery of the Shares to be sold by such Selling Stockholder and payment therefor
pursuant to this Agreement will pass valid title to such Shares, free and clear of any adverse
claim within the meaning of Section 8-102 of the New York Uniform Commercial Code, to the
Underwriter without notice of an adverse claim.
(e) Such Selling Stockholder is not prompted to sell Shares pursuant to this Agreement by any
material non-public information concerning the Company or its subsidiaries that is not set forth in
the Time of Sale Prospectus.
(f) (i) The Registration Statement, when it became effective, did not contain and, as amended
or supplemented, if applicable, will not contain any untrue statement of a material fact or omit to
state a material fact required to be stated therein or necessary to make the statements therein not
misleading, (ii) the Time of Sale Prospectus does not, and at the time of each sale of the Shares
in connection with the offering when the Prospectus is not yet available to prospective purchasers
and at the Closing Date (as defined in Section 5), the Time of Sale Prospectus, as then
amended or supplemented by the Company, if applicable, will not, contain any untrue statement of a
material fact or omit to state a material fact necessary to make the statements therein, in the
light of the circumstances under which they were made, not misleading, and (iii) the Prospectus
does not contain and, as amended or supplemented, if applicable, will not contain any untrue
statement of a material fact or omit to state a material fact necessary to make the statements
therein, in the light of the circumstances under which they were made, not misleading; provided
that with respect to each Selling Stockholder, the representations and warranties set forth in this
paragraph 2(f) are limited to statements and omissions made in reliance upon information relating
to such Selling Stockholder furnished to the Company in writing by such Selling Stockholder
expressly for use in the Registration Statement, the Time of Sale Prospectus and the Prospectus or
any amendments or supplements thereto.
(g) Except for the free writing prospectuses, if any, identified in Schedule II
hereto, and electronic road shows, if any, each furnished to the Underwriter before first use, such
Selling Stockholder, including such Selling Stockholders agents and representatives, has not
prepared, used or referred to, and will not, without your prior consent, prepare, use or refer to,
any free writing prospectus.
3. Agreements to Sell and Purchase. Each Selling Stockholder, severally and not
jointly, hereby agrees to sell to the Underwriter, and the Underwriter, upon the basis of the
representations and warranties herein contained, but subject to the conditions hereinafter stated,
agrees to purchase from such Selling Stockholder at $19.00 a share (the Purchase Price)
the number of Shares set forth opposite such Selling Stockholders name in Schedule I.
- 11 -
The Company hereby agrees that, without the prior written consent of the Underwriter, it will
not, during the period ending 60 days after the date of the Prospectus, (1) offer, pledge, sell,
contract to sell, sell any option or contract to purchase, purchase any option or contract to sell,
grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly
or indirectly, any shares of Common Stock or any securities convertible into or exercisable or
exchangeable for Common Stock or (2) enter into any swap or other arrangement that transfers to
another, in whole or in part, any of the economic consequences of ownership of the Common Stock,
whether any such transaction described in clause (1) or (2) above is to be settled by delivery of
Common Stock or such other securities, in cash or otherwise or (3) file any registration statement
with the Commission relating to the offering of any shares of Common Stock or any securities
convertible into or exercisable or exchangeable for Common Stock.
The restrictions contained in the preceding paragraph shall not apply to (a) the Shares to be
sold hereunder, (b) the issuance by the Company of shares of Common Stock upon the exercise of an
option or warrant or the conversion of a security outstanding on the date hereof and disclosed in
the Time of Sale Prospectus or of which the Underwriter has been advised in writing, (c) the
issuance by the Company of shares or options to purchase shares of Common Stock pursuant to the
Companys equity plans disclosed in the Prospectus, (d) the filing by the Company of any
Registration Statement on Form S-8 or a successor form thereto or (e) the issuance by the Company
of up to 691,912 shares of Common Stock in connection with any acquisition, collaboration or other
strategic transaction involving the Company or any of its subsidiaries, provided that the
recipients thereof execute a lock-up agreement substantially in the form of Exhibit A
hereto.
4. Terms of Public Offering. The Selling Stockholders are advised by the Underwriter
that the Underwriter proposes to make a public offering of the Shares as soon after the
Registration Statement and this Agreement have become effective as in the Underwriters judgment is
advisable. The Selling Stockholders are further advised by the Underwriter that the Shares may be
offered from time to time for sale in one or more transactions on The NASDAQ Global Select Market,
in the over-the-counter market, through negotiated transactions or otherwise at market prices
prevailing at the time of sale, at prices related to prevailing market prices or at negotiated
prices.
5. Payment and Delivery. Payment for the Shares to be sold by each Selling
Stockholder shall be made to such Selling Stockholder in Federal or other funds immediately
available in New York City against delivery of such Shares for the account of the Underwriter at
10:00 a.m., New York City time, on July 27, 2011, or at such other time on the same or such other
date, not later than the fifth business day thereafter, as shall be designated in writing by the
Underwriter. The time and date of such payment are hereinafter referred to as the Closing
Date.
The Shares shall be registered in such names and in such denominations as the Underwriter
shall request in writing not later than one full business day prior to the Closing Date. The
Shares shall be delivered to the Underwriter on the Closing Date for the account of the
Underwriter, with any transfer taxes payable in connection with the transfer of the Shares to the
Underwriter duly paid, against payment of the Purchase Price therefor.
- 12 -
6. Conditions to the Underwriters Obligations. The obligations of the Underwriter
are subject to the following conditions:
(a) Subsequent to the execution and delivery of this Agreement and prior to the Closing Date:
(i) there shall not have occurred any downgrading, nor shall any notice have been given
of any intended or potential downgrading or of any review for a possible change that does
not indicate the direction of the possible change, in the rating accorded any of the
securities of the Company or any of its subsidiaries by any nationally recognized
statistical rating organization, as such term is defined for purposes of Rule 436(g)(2)
under the Securities Act; and
(ii) there shall not have occurred any change, or any development involving a
prospective change, in the condition, financial or otherwise, or in the earnings, business
or operations of the Company and its subsidiaries, taken as a whole, from that set forth in
the Time of Sale Prospectus (excluding any amendments or supplements thereto) that, in your
judgment, is material and adverse and that makes it, in your judgment, impracticable to
market the Shares on the terms and in the manner contemplated in the Time of Sale
Prospectus.
(b) The Underwriter shall have received on the Closing Date a certificate, dated the Closing
Date and signed by an executive officer of the Company, to the effect set forth in Section
6(a)(i) above and to the effect that the representations and warranties of the Company
contained in this Agreement are true and correct as of the Closing Date and that the Company has
complied in all material respects with all of the agreements and satisfied all of the conditions on
its part to be performed or satisfied hereunder on or before the Closing Date. The officer signing
and delivering such certificate may rely upon the best of his or her knowledge as to proceedings
threatened.
(c) The Underwriter shall have received on the Closing Date an opinion of Wilmer Cutler
Pickering Hale and Dorr LLP, outside counsel for the Company, dated the Closing Date, in the form
attached hereto as Exhibit B.
(d) Stephen V.R. Whitman, Esq., general counsel to the Company, shall have furnished to the
Underwriter his written opinion, dated as the Closing Date, in form and substance satisfactory to
the Underwriter, to the effect that the compliance by the Company with all of the provisions of
this Agreement and the consummation of the transactions herein contemplated will not conflict with
or result in a breach or violation of any of the terms or provisions of, or constitute a default
under, any indenture, mortgage, deed of trust, loan agreement or other material agreement or
instrument to which the Company or any of its subsidiaries is a party or by which the Company or
any of its subsidiaries is bound or by which any of the property or assets of the Company or any of
its subsidiaries is subject.
(e) The Underwriter shall have received on the Closing Date an opinion of Latham & Watkins
LLP, counsel for Carlyle Partners IV, L.P. and CP IV Coinvestment, L.P. (collectively, the
Carlyle Entities), dated the Closing Date, in the form attached hereto as Exhibit
C.
- 13 -
(f) The Underwriter shall have received on the Closing Date an opinion of Goodwin Procter
LLP, counsel for the Underwriter, dated the Closing Date, with respect to such matters as the
Underwriter may reasonably request.
With respect to paragraphs (a), (b), (c) and (d) of the form of opinion attached hereto as
Exhibit B, Wilmer Cutler Pickering Hale and Dorr LLP may state that its statements and
beliefs therein are based upon their participation in the preparation of the Registration
Statement, the Time of Sale Prospectus and the Prospectus and any amendments or supplements thereto
and review and discussion of the contents thereof, but are without independent check or
verification, except as specified. With respect to the opinions in the third sentence of paragraph
one and the third sentence of paragraph two of the form of opinion attached hereto as Exhibit
B, Wilmer Cutler Pickering Hale and Dorr LLP may rely upon an opinion or opinions of counsel
for such subsidiaries; provided that (A) each such counsel for such subsidiaries is reasonably
satisfactory to your counsel and (B) a copy of each opinion so relied upon is delivered to the
Underwriter and is in form and substance reasonably satisfactory to the Underwriters counsel.
The opinion of Wilmer Cutler Pickering Hale and Dorr LLP described in Section 6(c)
above and the opinion of Latham & Watkins LLP described in Section 6(e) above, shall be
rendered to the Underwriter at the request of the Company or one or more of the Selling
Stockholders, as the case may be, and shall so state therein.
(g) The Underwriter shall have received, on each of the date hereof and the Closing Date, a
letter dated the date hereof or the Closing Date, as the case may be, in form and substance
reasonably satisfactory to the Underwriter, from PricewaterhouseCoopers LLP, independent public
accountants, containing statements and information of the type ordinarily included in accountants
comfort letters to underwriters with respect to the financial statements and certain financial
information contained or incorporated by reference in the Registration Statement, the Time of Sale
Prospectus and the Prospectus; provided that the letter delivered on the Closing Date shall use a
cut-off date not earlier than the date hereof.
(h) The lock up agreements, each substantially in the form of Exhibit A hereto,
between the Underwriter and the Selling Stockholders relating to sales and certain other
dispositions of shares of Common Stock or certain other securities, delivered to the Underwriter on
or before the date hereof, shall be in full force and effect on the Closing Date.
7. Covenants of the Company. The Company covenants with the Underwriter as follows:
(a) To furnish to the Underwriter, without charge, a signed copy of the Registration Statement
(including exhibits thereto) and to furnish to the Underwriter in New York City, without charge,
prior to 10:00 a.m. New York City time on the business day next succeeding the date of this
Agreement and during the period mentioned in Sections 7(e) or 7(f) below, as many
copies of the Time of Sale Prospectus, the Prospectus and any supplements and amendments thereto or
to the Registration Statement as the Underwriter may reasonably request.
(b) Before amending or supplementing the Registration Statement, the Time of Sale Prospectus
or the Prospectus, to furnish to the Underwriter a copy of each such proposed
- 14 -
amendment or supplement and not to file any such proposed amendment or supplement to which the
Underwriter reasonably objects, and to file with the Commission within the applicable period
specified in Rule 424(b) under the Securities Act any prospectus required to be filed pursuant to
such Rule.
(c) To furnish to the Underwriter a copy of each proposed free writing prospectus to be
prepared by or on behalf of, used by, or referred to by the Company and not to use or refer to any
proposed free writing prospectus to which the Underwriter reasonably objects.
(d) Not to take any action that would result in the Underwriter or the Company being required
to file with the Commission pursuant to Rule 433(d) under the Securities Act a free writing
prospectus prepared by or on behalf of the Underwriter that the Underwriter otherwise would not
have been required to file thereunder.
(e) If the Time of Sale Prospectus is being used to solicit offers to buy the Shares at a time
when the Prospectus is not yet available to prospective purchasers and any event shall occur or
condition exist as a result of which it is necessary to amend or supplement the Time of Sale
Prospectus in order to make the statements therein, in the light of the circumstances, not
misleading, or if any event shall occur or condition exist as a result of which the Time of Sale
Prospectus conflicts with the information contained or incorporated by reference in the
Registration Statement then on file, or if, in the opinion of counsel for the Underwriter, it is
necessary to amend or supplement the Time of Sale Prospectus to comply with applicable law,
forthwith to prepare, file with the Commission and furnish, at its own expense, to the Underwriter
and to any dealer upon request, either amendments or supplements to the Time of Sale Prospectus so
that the statements in the Time of Sale Prospectus as so amended or supplemented will not, in the
light of the circumstances when the Time of Sale Prospectus is delivered to a prospective
purchaser, be misleading or so that the Time of Sale Prospectus, as amended or supplemented, will
no longer conflict with the Registration Statement, or so that the Time of Sale Prospectus, as
amended or supplemented, will comply with applicable law.
(f) If, during such period after the first date of the public offering of the Shares as in the
opinion of counsel for the Underwriter the Prospectus (or in lieu thereof the notice referred to in
Rule 173(a) of the Securities Act) is required by law to be delivered in connection with sales by
the Underwriter or a dealer, any event shall occur or condition exist as a result of which it is
necessary to amend or supplement the Prospectus in order to make the statements therein, in the
light of the circumstances when the Prospectus (or in lieu thereof the notice referred to in Rule
173(a) of the Securities Act) is delivered to a purchaser, not misleading, or if, in the opinion of
counsel for the Underwriter, it is necessary to amend or supplement the Prospectus to comply with
applicable law, forthwith to prepare, file with the Commission and furnish, at its own expense, to
the Underwriter and to the dealers (whose names and addresses the Underwriter will furnish to
the Company) to which Shares may have been sold by the Underwriter and to any other dealers upon
request, either amendments or supplements to the Prospectus so that the statements in the
Prospectus as so amended or supplemented will not, in the light of the circumstances when the
Prospectus (or in lieu thereof the notice referred to in Rule 173(a) of the Securities Act) is
delivered to a purchaser, be misleading or so that the Prospectus, as amended or supplemented, will
comply with applicable law.
- 15 -
(g) To endeavor to qualify the Shares for offer and sale under the securities or Blue Sky
laws of such jurisdictions as the Underwriter shall reasonably request; provided that in no event
shall the Company or any of its subsidiaries be obligated to qualify to do business in any
jurisdiction where it is not now so qualified or to take any action that would subject it to
service of process in suits in any jurisdiction where it is not now subject or to subject itself to
taxation in excess of a nominal amount in respect of doing business in any jurisdiction.
(h) To make generally available to the Companys security holders and to the Underwriter as
soon as practicable an earning statement covering a period of at least twelve months beginning with
the first fiscal quarter of the Company occurring after the date of this Agreement which shall
satisfy the provisions of Section 11(a) of the Securities Act and the rules and regulations of the
Commission thereunder.
8. Expenses. Whether or not the transactions contemplated in this Agreement are
consummated or this Agreement is terminated, the Company agrees to pay or cause to be paid all
expenses incident to the performance of its obligations under this Agreement, including: (i) the
fees, disbursements and expenses of the Companys counsel and the Companys accountants in
connection with the registration and delivery of the Shares under the Securities Act and all other
fees or expenses in connection with the preparation and filing of the Registration Statement, the
Time of Sale Prospectus, the Prospectus, any free writing prospectus prepared by or on behalf of,
used by, or referred to by the Company and amendments and supplements to any of the foregoing,
including all printing costs associated therewith, and the mailing and delivering of copies thereof
to the Underwriter and dealers, in the quantities hereinabove specified, (ii) all costs and
expenses related to the transfer and delivery of the Shares to the Underwriter, including any
transfer or other taxes payable thereon, (iii) the cost of printing or producing any Blue Sky or
Legal Investment memorandum in connection with the offer and sale of the Shares under state
securities laws and all expenses in connection with the qualification of the Shares for offer and
sale under state securities laws as provided in Section 7(g) hereof, including filing fees
and the reasonable fees and disbursements of counsel for the Underwriter in connection with such
qualification and in connection with the Blue Sky or Legal Investment memorandum, (iv) all filing
fees and the reasonable fees and disbursements of counsel to the Underwriter incurred in connection
with the review and qualification of the offering of the Shares by FINRA, (v) all costs and
expenses incident to listing the Shares on The NASDAQ Global Select Market, (vi) the cost of
printing certificates representing the Shares, (vii) the costs and charges of any transfer agent,
registrar or depositary, (viii) the costs and expenses of the Company relating to investor
presentations on any road show undertaken in connection with the marketing of the offering of the
Shares, including, without limitation, expenses associated with the preparation or dissemination of
any electronic road show, expenses associated with the production of road show slides and graphics,
fees and expenses of any consultants engaged in connection with the road show presentations with
the prior approval of the Company, travel and lodging expenses of the representatives and officers
of the Company and any such consultants, and half of the cost of any aircraft chartered in
connection with the road show, (ix) the document production charges and expenses associated with
printing this Agreement and (x) all other costs and expenses incident to the performance of the
obligations of the Company hereunder for which provision is not otherwise made in this Section
8. It is understood, however, that except as provided in this Section 8, Section
10 entitled Indemnity and Contribution and the last paragraph of Section 12 below,
the Underwriter will pay all of its costs and expenses, including fees and disbursements
- 16 -
of their counsel, stock transfer taxes payable on resale of any of the Shares by it and any
advertising expenses connected with any offers it may make and travel and lodging expenses of the
representatives of the Underwriter in connection with the road show. In addition, the Underwriter
will pay half of the cost of any aircraft chartered in connection with the road show.
The provisions of this Section 8 shall not supersede or otherwise affect any agreement
that the Selling Stockholders and the Company may otherwise have for the allocation of such
expenses among themselves.
9. Covenants of the Underwriter. The Underwriter covenants with the Company not to
take any action that would result in the Company being required to file with the Commission under
Rule 433(d) under the Securities Act a free writing prospectus prepared by or on behalf of the
Underwriter that otherwise would not be required to be filed by the Company thereunder, but for the
action of the Underwriter.
10. Indemnity and Contribution. (a) The Company agrees to indemnify and hold harmless
the Underwriter, its directors and officers, each person, if any, who controls the Underwriter
within the meaning of either Section 15 of the Securities Act or Section 20 of the Exchange Act,
and each affiliate of the Underwriter within the meaning of Rule 405 under the Securities Act from
and against any and all losses, claims, damages and liabilities (including, without limitation, any
legal or other expenses reasonably incurred in connection with defending or investigating any such
action or claim) caused by any untrue statement or alleged untrue statement of a material fact
contained in the Registration Statement or any amendment thereof, the Time of Sale Prospectus, any
issuer free writing prospectus as defined in Rule 433(h) under the Securities Act, any Company
information that the Company has filed, or is required to file, pursuant to Rule 433(d) under the
Securities Act, or the Prospectus or any amendment or supplement thereto, or caused by any omission
or alleged omission to state therein a material fact required to be stated therein or necessary to
make the statements therein not misleading, except insofar as such losses, claims, damages or
liabilities are caused by any such untrue statement or omission or alleged untrue statement or
omission based upon information relating to the Underwriter furnished to the Company in writing by
the Underwriter expressly for use therein.
(b) Each of the Selling Stockholders, severally and not jointly, agrees to indemnify and hold
harmless the Underwriter, its directors and officers, each person, if any, who controls the
Underwriter within the meaning of either Section 15 of the Securities Act or Section 20 of the
Exchange Act, and each affiliate of the Underwriter within the meaning of Rule 405 under the
Securities Act from and against any and all losses, claims, damages and liabilities (including,
without limitation, any legal or other expenses reasonably incurred in connection with defending or
investigating any such action or claim) caused by any untrue statement or alleged untrue statement
of a material fact contained in the Registration Statement or any amendment thereof, the Time of
Sale Prospectus, any issuer free writing prospectus as defined in Rule 433(h) under the Securities
Act, any Company information that the Company has filed, or is required to file, pursuant to Rule
433(d) under the Securities Act, or the Prospectus or any amendment or supplement thereto, or
caused by any omission or alleged omission to state therein a material fact required to be stated
therein or necessary to make the statements therein not misleading, in each case to the extent, but
only to the extent, that such untrue statement or alleged untrue statement or omission or alleged
omission was made in the Registration Statement, the Time of Sale
- 17 -
Prospectus, any issuer free writing prospectus, the Prospectus or any such amendment or
supplement in reliance upon and in conformity with written information furnished to the Company by
such Selling Stockholder expressly for use therein. The liability of each Selling Stockholder
under the indemnity agreement contained in this paragraph shall be limited to an amount equal to
(i) the number of Shares sold by such Selling Stockholder under this Agreement multiplied by (ii)
the Public Offering Price (minus the related underwriting discounts and commissions).
(c) The Underwriter agrees to indemnify and hold harmless the Company, the Selling
Stockholders, the directors of the Company, the officers of the Company who sign the Registration
Statement and each person, if any, who controls the Company or any Selling Stockholder within the
meaning of either Section 15 of the Securities Act or Section 20 of the Exchange Act from and
against any and all losses, claims, damages and liabilities (including, without limitation, any
legal or other expenses reasonably incurred in connection with defending or investigating any such
action or claim) caused by any untrue statement or alleged untrue statement of a material fact
contained in the Registration Statement or any amendment thereof, the Time of Sale Prospectus, any
issuer free writing prospectus as defined in Rule 433(h) under the Securities Act, any Company
information that the Company has filed, or is required to file, pursuant to Rule 433(d) of the
Securities Act, or the Prospectus (as amended or supplemented if the Company shall have furnished
any amendments or supplements thereto), or caused by any omission or alleged omission to state
therein a material fact required to be stated therein or necessary to make the statements therein
not misleading, but only with reference to information relating to the Underwriter furnished to the
Company in writing by the Underwriter expressly for use in the Registration Statement, the Time of
Sale Prospectus, any issuer free writing prospectus or the Prospectus or any amendment or
supplement thereto.
(d) In case any proceeding (including any governmental investigation) shall be instituted
involving any person in respect of which indemnity may be sought pursuant to Section 10(a),
10(b) or 10(c), such person (the indemnified party) shall promptly notify
the person against whom such indemnity may be sought (the indemnifying party) in writing;
provided that (1) the failure to notify the indemnifying party shall not relieve it from any
liability it may have under such Sections except to the extent it has been materially prejudiced
through the forfeiture of substantive rights or defenses by such failure and (2) the failure to
notify the indemnifying party shall not relieve it from any liability it may have to an indemnified
party otherwise than under this Section 10. The indemnifying party, upon request of the
indemnified party, shall retain counsel reasonably satisfactory to the indemnified party to
represent the indemnified party and any others the indemnifying party may designate in such
proceeding and shall pay the reasonably incurred fees and disbursements of such counsel related to
such proceeding. In any such proceeding, any indemnified party shall have the right to retain its
own counsel, but the fees and expenses of such counsel shall be at the expense of such indemnified
party unless (i) the indemnifying party and the indemnified party shall have mutually agreed to the
retention of such counsel or (ii) the named parties to any such proceeding (including any impleaded
parties) include both the indemnifying party and the indemnified party and representation of both
parties by the same counsel would be inappropriate due to actual or potential differing interests
between them. It is understood that the indemnifying party shall not, in respect of the legal
expenses of any indemnified party in connection with any proceeding or related proceedings in the
same jurisdiction, be liable for (i) the fees and expenses of more than
- 18 -
one separate firm (in addition to any local counsel) for the Underwriter and all persons, if
any, who control the Underwriter within the meaning of either Section 15 of the Securities Act or
Section 20 of the Exchange Act or who are affiliates of the Underwriter within the meaning of Rule
405 under the Securities Act, (ii) the fees and expenses of more than one separate firm (in
addition to any local counsel) for the Company, its directors, its officers who sign the
Registration Statement and each person, if any, who controls the Company within the meaning of
either such Section and (iii) the fees and expenses of more than one separate firm (in addition to
any local counsel) for all Selling Stockholders and all persons, if any, who control any Selling
Stockholder within the meaning of either such Section, and that all such reasonably incurred fees
and expenses shall be reimbursed as they are incurred. In the case of any such separate firm for
the Company, and such directors, officers and control persons of the Company, such firm shall be
designated in writing by the Company. The indemnifying party shall not be liable for any
settlement of any proceeding effected without its written consent, but if settled with such consent
or if there be a final judgment for the plaintiff, the indemnifying party agrees to indemnify the
indemnified party from and against any loss or liability by reason of such settlement or judgment.
Notwithstanding the foregoing sentence, if at any time an indemnified party shall have requested an
indemnifying party to reimburse the indemnified party for fees and expenses of counsel as
contemplated by the first and second sentences of this paragraph, the indemnifying party agrees
that it shall be liable for any settlement of any proceeding effected without its written consent
if (i) such settlement is entered into more than 45 days after receipt by such indemnifying party
of the aforesaid request and (ii) such indemnifying party shall not have reimbursed the indemnified
party in accordance with such request prior to the date of such settlement. No indemnifying party
shall, without the prior written consent of the indemnified party, effect any settlement of any
pending or threatened proceeding in respect of which any indemnified party is or could have been a
party and indemnity could have been sought hereunder by such indemnified party, unless such
settlement includes an unconditional release of such indemnified party from all liability on claims
that are the subject matter of such proceeding.
(e) To the extent the indemnification provided for in Section 10(a), 10(b) or
10(c) is unavailable to an indemnified party or insufficient in respect of any losses,
claims, damages or liabilities referred to therein, then each indemnifying party under such
paragraph, in lieu of indemnifying such indemnified party thereunder, shall contribute to the
amount paid or payable by such indemnified party as a result of such losses, claims, damages or
liabilities (i) in such proportion as is appropriate to reflect the relative benefits received by
the indemnifying party or parties on the one hand and the indemnified party or parties on the other
hand from the offering of the Shares or (ii) if the allocation provided by clause 10(e)(i) above is
not permitted by applicable law, in such proportion as is appropriate to reflect not only the
relative benefits referred to in clause 10(e)(i) above but also the relative fault of the
indemnifying party or parties on the one hand and of the indemnified party or parties on the other
hand in connection with the statements or omissions that resulted in such losses, claims, damages
or liabilities, as well as any other relevant equitable considerations. The relative benefits
received by the Selling Stockholders on the one hand and the Underwriter on the other hand in
connection with the offering of the Shares shall be deemed to be in the same respective proportions
as the net proceeds from the offering of the Shares (before deducting expenses) received by each
Selling Stockholder and the total underwriting discounts and commissions received by the
Underwriter, in each case as set forth in the table on the cover of the Prospectus, bear to the
aggregate Public Offering Price of the Shares. The relative fault of the Selling Stockholders on
the one hand and
- 19 -
the Underwriter on the other hand shall be determined by reference to, among other things,
whether the untrue or alleged untrue statement of a material fact or the omission or alleged
omission to state a material fact relates to information supplied by the Selling Stockholders or by
the Underwriter and the parties relative intent, knowledge, access to information and opportunity
to correct or prevent such statement or omission. The liability of each Selling Stockholder under
the contribution agreement contained in this paragraph is several in proportion to the respective
number of Shares such Selling Stockholder has sold hereunder and shall be limited to an amount
equal to (i) the number of Shares sold by such Selling Stockholder under this Agreement multiplied
by (ii) the Public Offering Price (minus the related underwriting discounts and commissions).
(f) The Selling Stockholders and the Underwriter agree that it would not be just or equitable
if contribution pursuant to this Section 10 were determined by pro rata allocation (even if
the Selling Stockholders were treated as one entity for such purpose) or by any other method of
allocation that does not take account of the equitable considerations referred to in Section
10(e). The amount paid or payable by an indemnified party as a result of the losses, claims,
damages and liabilities referred to in Section 10(e) shall be deemed to include, subject to
the limitations set forth above, any legal or other expenses reasonably incurred by such
indemnified party in connection with investigating or defending any such action or claim.
Notwithstanding the provisions of this Section 10, the Underwriter shall not be required to
contribute any amount in excess of the amount by which the total price at which the Shares
underwritten by it and distributed to the public were offered to the public exceeds the amount of
any damages that the Underwriter has otherwise been required to pay by reason of such untrue or
alleged untrue statement or omission or alleged omission. No person guilty of fraudulent
misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to
contribution from any person who was not guilty of such fraudulent misrepresentation. The remedies
provided for in this Section 10 are not exclusive and shall not limit any rights or
remedies which may otherwise be available to any indemnified party at law or in equity.
(g) The indemnity and contribution provisions contained in this Section 10 and the
representations, warranties and other statements of the Company and the Selling Stockholders
contained in this Agreement shall remain operative and in full force and effect regardless of (i)
any termination of this Agreement, (ii) any investigation made by or on behalf of the Underwriter,
any person controlling the Underwriter or any affiliate of the Underwriter, any Selling Stockholder
or any person controlling any Selling Stockholder, or the Company, its officers or directors or any
person controlling the Company and (iii) acceptance of and payment for any of the Shares.
11. Termination. The Underwriter may terminate this Agreement by notice given to the
Company, if after the execution and delivery of this Agreement and prior to the Closing Date (i)
trading generally shall have been suspended or materially limited on, or by, as the case may be,
any of the New York Stock Exchange, the American Stock Exchange, The NASDAQ Global Select Market,
the Chicago Board of Options Exchange, the Chicago Mercantile Exchange or the Chicago Board of
Trade, (ii) trading of any securities of the Company shall have been suspended on any exchange or
in any over the counter market, (iii) a material disruption in securities settlement, payment or
clearance services in the United States shall have occurred, (iv) any moratorium on commercial
banking activities shall have been declared by Federal or New York
- 20 -
State authorities or (v) there shall have occurred any outbreak or escalation of hostilities,
or any change in financial markets or any calamity or crisis that, in your judgment, is material
and adverse and which, singly or together with any other event specified in this clause (v), makes
it, in your judgment, impracticable or inadvisable to proceed with the offer, sale or delivery of
the Shares on the terms and in the manner contemplated in the Time of Sale Prospectus or the
Prospectus.
If this Agreement shall be terminated by the Underwriter because of any failure or refusal on
the part of any Selling Stockholder to comply with the terms or to fulfill any of the conditions of
this Agreement, or if for any reason any Selling Stockholder shall be unable to perform its
obligations under this Agreement, the Selling Stockholders will reimburse the Underwriter for all
out of pocket expenses (including the fees and disbursements of their counsel) reasonably incurred
by the Underwriter in connection with this Agreement or the offering contemplated hereunder.
12. Effectiveness. This Agreement shall become effective upon the execution and
delivery hereof by the parties hereto.
13. Entire Agreement. (a) This Agreement, together with any contemporaneous written
agreements and any prior written agreements (to the extent not superseded by this Agreement) that
relate to the offering of the Shares, represents the entire agreement between the Company and the
Selling Stockholders, on the one hand, and the Underwriter, on the other, with respect to the
preparation of the Time of Sale Prospectus, the Prospectus, the conduct of the offering, and the
purchase and sale of the Shares.
(b) The Company acknowledges that in connection with the offering of the Shares: (i) the
Underwriter has acted at arms length, is not an agent of, and owes no fiduciary duties to, the
Company or any other person, (ii) the Underwriter owes the Company only those duties and
obligations set forth in this Agreement and prior written agreements (to the extent not superseded
by this Agreement), if any, and (iii) the Underwriter may have interests that differ from those of
the Company. The Company waives to the full extent permitted by applicable law any claims it may
have against the Underwriter arising from an alleged breach of fiduciary duty in connection with
the offering of the Shares.
14. Applicable Law. This Agreement shall be governed by and construed in accordance
with the internal laws of the State of New York.
15. Headings. The headings of the sections of this Agreement have been inserted for
convenience of reference only and shall not be deemed a part of this Agreement.
16. Notices. All communications hereunder shall be in writing and effective only upon
receipt and if to the Underwriter shall be delivered, mailed or sent to Barclays Capital Inc., 745
Seventh Avenue, New York, New York 10019, Attention: Syndicate Registration, with a copy to Goodwin
Procter LLP, Exchange Place, Boston, Massachusetts 02109, Attention: Mark T. Bettencourt; and if to
the Company shall be delivered, mailed or sent to SS&C Technologies Holdings, Inc., 80 Lamberton
Road, Windsor, Connecticut 06095, Attention: Chief Executive Officer, with a copy to the General
Counsel and a copy to Wilmer Cutler Pickering Hale and
- 21 -
Dorr LLP, 60 State Street, Boston, Massachusetts 02109, Attention: David A. Westenberg; and if
to the Carlyle Entities shall be delivered, mailed or sent to The Carlyle Group, 128 South Tryon
Street, Suite 1550, Charlotte, NC 28202, Attention: Cam Dyer, with a copy to Latham & Watkins LLP,
555 11th Street NW, Washington, DC 20016, Attention: Patrick Shannon.
17. Counterparts. This Agreement may be signed in two or more counterparts, each of
which shall be an original, with the same effect as if the signatures thereto and hereto were upon
the same instrument.
[Remainder of page intentionally left blank]
- 22 -
Very truly yours, SS&C Technologies Holdings, Inc. |
||||
By: | /s/ Patrick J. Pedonti | |||
Name: | Patrick J. Pedonti | |||
Title: | Senior Vice President and Chief Financial Officer | |||
CARLYLE PARTNERS IV, L.P., a Delaware limited partnership |
||||
By: | TC Group IV, L.P., its General Partner | |||
By: | TC Group IV Managing GP, L.L.C., its General Partner | |||
By: | TC Group, L.L.C., its Managing Member | |||
By: | TCG Holdings, L.L.C., its Managing Member | |||
By: | /s/ Jeremy W. Anderson | |||
Name: | Jeremy W. Anderson | |||
Title: | Authorized Person | |||
CP IV COINVESTMENT, L.P., a Delaware limited partnership |
||||
By: | TC Group IV, L.P., its General Partner | |||
By: | TC Group IV Managing GP, L.L.C., its General Partner | |||
By: | TC Group, L.L.C., its Managing Member | |||
By: | TCG Holdings, L.L.C., its Managing Member | |||
By: | /s/ Jeremy W. Anderson | |||
Name: | Jeremy W. Anderson | |||
Title: | Authorized Person | |||
[Signature Page to Underwriting Agreement]
Accepted as of the date hereof |
||||
By: | BARCLAYS CAPITAL INC. | |||
By: | /s/ Victoria Hale | |||
Name: | Victoria Hale | |||
Title: | Vice President | |||
[Signature Page to Underwriting Agreement]
SCHEDULE I
Selling Stockholders
Number of | ||||
Shares | ||||
Selling Stockholder | To Be Sold | |||
Carlyle Partners IV, L.P.
|
6,728,267 | |||
CP IV Coinvestment, L.P.
|
271,733 | |||
Total:
|
7,000,000 | |||
Schedule I Page 1
SCHEDULE II
Time of Sale Prospectus
1. | Free writing prospectuses: July 21, 2011 | |
2. | Orally conveyed public offering price per share |
Exhibit C Page 1